Precision Immunotherapy in Axial SpA
Dr. Marina Magrey at the 2024 ACR Convergence meeting in Washington, DC.
Watch video →What's hot
View all perspectives
What's Hot
PsA: Impact of Sex
Dr. Arthur Kavanaugh discusses abstracts 1709 and 1471, along with a related seminar, presented at the 2024 ACR Convergence meeting in Washington, DC.
Watch video →
Cycling vs Switching after TNFi Failure in axSpA
Dr. Lihi Eder discusses abstract 0603, presented at the 2024 ACR Convergence meeting in Washington, DC.
Watch video →
A Fibroblast Renaissance
Dr. Andrea Fava at the 2024 ACR Convergence meeting in Washington, DC.
Watch video →
ICYMI: Sex related differences in PsA
Different factors are known to influence disease characteristics and outcomes in psoriatic arthritis (PsA).
Read more →
Palliative Care in Rheumatology
Dr. Jiha Lee talks with Dr. Shannon Herndon about abstracts 0204 and 1064, presented at the 2024 ACR Convergence meeting in Washington, DC.
Watch video →
Efficacy and Safety of Nipocalimab for Sjogren's Syndrome
Dr. Mike Putman reports on abstract 2527, Efficacy and Safety of Nipocalimab, an Anti-FcRn Monoclonal Antibody, in Primary Sjogren’s Disease: Results from a Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study (DAHLIAS), presented at the 2024 ACR Convergence meeting in Washington, DC.
Watch video →
ICYMI: Say Goodbye to Methotrexate in PMR?
For decades, glucocorticoids (GCs) have formed the backbone of polymyalgia rheumatica (PMR) management.
Read more →
Predicting Flares in Rheumatoid Arthritis
Dr. Jonathan Kay interviews Dr. John Isaacs about abstract 1349, presented at the 2024 ACR Convergence meeting in Washington, DC.
Watch video →
ICYMI: ORAL Surveillance - Is Statin Use the Problem/Solution?
The findings from ORAL Surveillance Study have been a dominant conversation at recent ACR Convergence, with the seminal findings and subsequent analyses a target of debate. Subsequent post-hoc analyses, follow-up studies, and claims data analyses have been used to further interpret the data, though a clear answer on safety is not certain. A study presented on Sunday reported on a new post-hoc analysis that provides new insights.
Read more →
Are we under-monitoring in scleroderma ILD?
Dr. Janet Pope discusses abstract 0678, Patients with Interstitial Lung Disease Due to Systemic Sclerosis or Rheumatoid Arthritis Need Monitoring More Frequently Than Annually, and abstract 0706, Single Center Prospective Cohort of Systemic Sclerosis Patients Who Are At-Risk for Pulmonary Hypertension, presented at the 2024 ACR Convergence meeting in Washington, DC.
Watch video →
Sex Differences in Psoriatic Arthritis
Dr. Catherine Bakewell shared key takeaways from a session presented Sunday morning by Dr. Laura Coates and Dr. Lihi Eder, as well as abstract 1709, presented at the 2024 ACR Convergence meeting in Washington, DC. 1709
Watch video →
ICYMI: Evaluation of Bimekizumab in PsA
Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)‑17A and F. There have been more updates on the 2 year data on BKZ at #ACR24, and this is a summary of four studies being presented this year at ACR24.
Read more →
ICYMI: Shifting Trends in Initial RA Treatment Approaches
A recent study by Sparks et al reveals evolving trends in DMARD usage for rheumatoid arthritis over two decades in the United States. This retrospective analysis evaluated 407,728 DMARD initiation episodes among 229,365 unique patients from 2001 to 2021.
Read more →
ICYMI: Taking CAR-T for a Test Drive
When the ACR Convergence 2024 abstract site went live, the first query I typed into the search bar was, “CAR-T.” I consider myself a CAR-T skeptic and would be surprised if the magical results from this NEJM case series replicate at scale, but it seems likely that CAR-T will revolutionize the care for (some) patients with rheumatic diseases.
Read more →
The Psoriatic March: PsA before PsO
Dr. Antoni Chan discusses abstract 2328, presented at the 2024 ACR Convergence meeting in Washington, DC.
Watch video →
A useful urinary biomarker for lupus nephritis
Dr. Andrea Fava discusses plenary abstract 1642, presented at the 2024 ACR Convergence meeting in Washington, DC.
Watch video →
Dreaming of Relief: The Importance of Sleep in Lupus and Rheumatoid Arthritis
Sleep plays a critical role in regulating inflammation and overall health. In rheumatic diseases like lupus and rheumatoid arthritis (RA), disrupted sleep is common and can exacerbate symptoms and disease progression. Experts Dr. Al Kim, Patty Katz, and Dr. Yvonne Lee emphasized the importance of addressing sleep disturbances in these conditions.
Read more →
sheila RHEUMarampa
11 months 1 week ago
LEVI-04 a novel neurotropin3-i showed:
-significant analgesia across all measures
-improvement in functional measures and PGA for all doses in a Ph2 RCT
- well tolerated
Hopefully will prove to be a therapeutic option for knee #osteoarthritis in future
@RheumNow #ACR24 absL15 https://t.co/kWsyyyGxyU
Antoni Chan MD (Prof) synovialjoints
11 months 1 week ago
Late breaking abstract L19
Study on the efficacy & safety of Emapalumab in treating Macrophage Activation Syndrome (MAS) in Still's Disease.
Key findings:
- 53.8% achieved complete response (CR) at Week 8; 85% at any time.
- Rapid reduction in hyperinflammation biomarkers… https://t.co/VcmUdRP6PV https://t.co/r7AMt0IjYk
Richard Conway RichardPAConway
11 months 1 week ago
Grom et al. Emapalumab (anti-IFNg) in MAS in Stills. 39 patient pooled analysis. 54% complete response at week 8, 85% at any time. Clinically meaningful glucocorticoid reduction in 72%. @RheumNow #ACR24 Abstr#L19 https://t.co/U72KCfsUh7 https://t.co/jNxsvhseVf
One of the hot topics during the meeting was gender differences in SpA. Three abstracts presented addressed issues related to these differences particularly in the aspects of treatment response and disease activity.
Janet Pope Janetbirdope
11 months 1 week ago
Sustained Complete Renal Remission
➡️v strict endpoint in #lupus #nephritis trial from 1 yr to 3yr f/u
▶️all added to #LN SoC
#Voclosporin 20.1% vs #placebo 11.8%
Better if 1 visit only didn’t meet endpoint
➡️ then 10% more per group
ACRBest ACR24 @ACRheum @RheumNow abst1545
Richard Conway RichardPAConway
11 months 1 week ago
Conaghan et al. LEVI-04, neurotrophin-3 inhibitor in knee OA. 518 patients. Significant improvements in WOMAC pain and function, and PGA. So sign of any increase in rapidly progressive OA (as with NGF inhibitors) @RheumNow #ACR24 Abstr#L15 https://t.co/qud4wTAikY https://t.co/0wjjG4U4bf
Antoni Chan MD (Prof) synovialjoints
11 months 1 week ago
Late breaking abstract L16
Dapirolizumab Pegol showed significant improvement in SLE disease activity in our Phase 3 trial.
Key findings:
- 49.5% of patients achieved BICLA response at Week 48 vs 34.6% on placebo (p=0.0110).
- 60.1% achieved SRI-4 response vs 41.1% on placebo… https://t.co/ZawdsLOxmK https://t.co/gpV3KayIW1
Mike Putman EBRheum
11 months 1 week ago
PHOENYCS GO, RCT of dapirplizumab, novel CD40Li in SLE
Met primary endpoint (NNT~6 for BICLA) & numerical improvements in many other endpts
1 MI & 1 death from infection over 213 pts
Encouraging for sure! Second phase 3 being launched
#ACR24 @RheumNow Abstr#L16 #ACRbest https://t.co/QwDMKjhFvb
Dr. John Cush RheumNow
11 months 1 week ago
RheumNow’s expanded coverage of the #ACR24 Annual meeting is sponsored in part by Novartis. All content is chosen by RheumNow & its faculty
Janet Pope Janetbirdope
11 months 1 week ago
In order to have a
#DMOAD in knee #osteoarthritis
➡️ early detection may be v important
Study of early pt Symptoms was done
2/3 had pain
1/2 #joint Swelling
Need biomarkers & sensitive imaging in early #OA as symptoms are
NOT uniform
#ACR24 @RheumNow @ACRheum abst2111 https://t.co/K94m9rOjtP
Janet Pope Janetbirdope
11 months 1 week ago
Pts w #osteoarthritis and T2 DM
👇
Who Have
⬆️pain
Have
worse control of #diabetes
Even after adjusting for #BMI
Chicken or egg - which comes 1st
🤷♀️
#ACR24 @RheumNow @ACRheum
Abst#2110 https://t.co/eN2xAw0EMG
Janet Pope Janetbirdope
11 months 1 week ago
Does #hand #osteoarthritis
Benefit from
#traction #splinting?
Nope 👎
Small 2 site #RCT - not helpful
I may Recommend #splinting - sometimes pts get
Pain relief - in my opinion
but this one didn’t help
#ACR24 @RheumNow @ACRheum
Abst#2108 https://t.co/K0Ud7uCb1P
Janet Pope Janetbirdope
11 months 1 week ago
How long is a long acting #intra-articular #steroid #injection in #knee #osteoarthritis?
#IA steroids can be q3monthly
#RCT of IA #fluticasone #propionate
Was superior to #placebo
Seemed to last approx 24 weeks
➡️ sub analysis in moderate pain, BMI<30
#ACR24 @RheumNow #2106 https://t.co/QBFCqXd1Q8
Janet Pope Janetbirdope
11 months 1 week ago
#Scleroderma #molecular #signatures in #skin predict long term outcomes
👇worst with inflammatory signature
This may have clinical and trial applicability
Nice work!
Abst0711 #ACR24 @RheumNow @ACRheum https://t.co/3CFxu6bACu
Poster Hall